Kedrion Urges Early Diagnosis and Awareness for Rising Secondary Immunodeficiencies at ESID 2026

Addressing Secondary Immunodeficiencies: Key Insights from ESID 2026

At the recent ESID 2026 conference held in Maastricht, Netherlands, a critical dialogue began regarding the increasing health challenge posed by Secondary Immunodeficiencies (SIDs). With a surge in patients affected due to the expanded use of immunosuppressive therapies and biologics, it has become imperative for the healthcare community to improve recognition and management of SIDs.

Professionals from various sectors—including physicians, researchers, and patients’ advocates—gathered to spark discussions aimed at enhancing understanding and care for those living with SIDs. One prevailing concern is the current lag in diagnosis and the consequences that follow. Many patients present with delayed recognition, heightening their risk for recurrent infections and diminished quality of life.

As Johan Prevot, Executive Director of IPOPI, noted, while recognition of SIDs has seen progress, disparities in awareness and support persist across different nations. A significant segment of SID patients may actually have underlying Primary Immunodeficiencies (PIDs) that have gone undiagnosed. Elevating the dialogue around these conditions is essential for ensuring patients receive the correct assistance and care.

Dr. Silvia Sánchez-Ramón, Head of the Immunology Department at La Paz University Hospital, emphasized the need for strengthened collaboration among healthcare specialties. Implementing standardized practices based on evidence can significantly expedite diagnosis and facilitate better patient outcomes.

Furthermore, Gorana Dasic, Vice President at Kedrion Biopharma, highlighted that advancing clinical management for these conditions hinges on fostering multidisciplinary partnerships, intertwining scientific research with practical clinical applications. Kedrion’s participation in research collaborations aims to strengthen resources that lead to timely diagnosis and informed patient care.

Kedrion also showcased its initiatives at the conference. Two posters were presented: one covering safety data from an Immunoglobulin therapy, and another focusing on the MAPPA survey initiative, which solicits insights from individuals living with Primary Immunodeficiencies throughout Europe. This project not only strengthens Kedrion's ties with patient organizations but also aims to amplify patient voices by collecting direct feedback from the community.

The MAPPA project is particularly significant as it expands from Italy to countries like Spain, Portugal, and Turkey, highlighting patient experiences in diverse healthcare settings. Preliminary findings reveal alarming trends, where over half of survey participants received their diagnosis after 18 years of age, with a staggering 28% reporting lasting health impacts due to diagnostic delays.

Alessandro Segato, President of AIP APS, reinforced the importance of integrating patient experiences into decision-making. The MAPPA survey's real-life patient data serves as a foundation for understanding unmet needs and can help drive improvements in healthcare delivery across Europe.

In conclusion, Kedrion's commitment to advancing knowledge around Secondary Immunodeficiencies and fostering collaborative efforts is paramount as the global healthcare landscape evolves. The challenges posed by SIDs require urgent attention and a unified approach to improve early diagnosis, patient support, and overall outcomes for affected individuals.

For more information about Kedrion Biopharma’s initiatives and their contribution to this pressing healthcare issue, visit Kedrion’s website.